127 related articles for article (PubMed ID: 37357111)
21. The Impact of Additional Para-aortic Dissection During Pancreaticoduodenectomy for Resectable Pancreatic Cancer.
Shen Z; Chen H; Zhao S; Ji Y; Zhou Y; Weng Y; Zhang J; Deng X; Peng C; Wang W; Shen B
Ann Surg Oncol; 2023 Mar; 30(3):1474-1482. PubMed ID: 36305986
[TBL] [Abstract][Full Text] [Related]
22. Prognostic impact of para-aortic lymph node status in resected pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous neoplasm - Time to consider a reclassification?
Linder S; Holmberg M; Engstrand J; Ghorbani P; Sparrelid E
Surg Oncol; 2022 May; 41():101735. PubMed ID: 35287096
[TBL] [Abstract][Full Text] [Related]
23. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.
Nagakawa Y; Sahara Y; Hosokawa Y; Murakami Y; Yamaue H; Satoi S; Unno M; Isaji S; Endo I; Sho M; Fujii T; Takishita C; Hijikata Y; Suzuki S; Kawachi S; Katsumata K; Ohta T; Nagakawa T; Tsuchida A
Ann Surg Oncol; 2019 Jun; 26(6):1629-1636. PubMed ID: 30610555
[TBL] [Abstract][Full Text] [Related]
24. Para-aortic lymph node involvement should not be a contraindication to resection of pancreatic ductal adenocarcinoma.
Pande R; Chughtai S; Ahuja M; Brown R; Bartlett DC; Dasari BV; Marudanayagam R; Mirza D; Roberts K; Isaac J; Sutcliffe RP; Chatzizacharias NA
World J Gastrointest Surg; 2022 May; 14(5):429-441. PubMed ID: 35734625
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.
Mokdad AA; Minter RM; Zhu H; Augustine MM; Porembka MR; Wang SC; Yopp AC; Mansour JC; Choti MA; Polanco PM
J Clin Oncol; 2017 Feb; 35(5):515-522. PubMed ID: 27621388
[TBL] [Abstract][Full Text] [Related]
26. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
Harrison JM; Wo JY; Ferrone CR; Horick NK; Keane FK; Qadan M; Lillemoe KD; Hong TS; Clark JW; Blaszkowsky LS; Allen JN; Castillo CF
Ann Surg Oncol; 2020 May; 27(5):1400-1406. PubMed ID: 31758284
[TBL] [Abstract][Full Text] [Related]
27. Role of Conversion Surgery for Unresectable Pancreatic Cancer After Long-Term Chemotherapy.
Tsuchiya N; Matsuyama R; Murakami T; Yabushita Y; Sawada Y; Kumamoto T; Endo I
World J Surg; 2020 Aug; 44(8):2752-2760. PubMed ID: 32291503
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis.
Uson Junior PLS; Carvalho L; Fernandes MLC; Botrus G; de Souza Martins R; da Silva EF; Dos Santos SSMB; Taniwaki L; Taranto P; Dutra ACP; de Oliveira Filho JB; Araujo SEA; Moura F
Sci Rep; 2022 Aug; 12(1):13592. PubMed ID: 35948602
[TBL] [Abstract][Full Text] [Related]
29. Prognostic impact of intraoperative peritoneal cytology after neoadjuvant therapy for potentially resectable pancreatic cancer.
Aoki S; Mizuma M; Hayashi H; Yoshimachi S; Hata T; Miura T; Takadate T; Maeda S; Ariake K; Kawaguchi K; Masuda K; Ishida M; Ohtsuka H; Nakagawa K; Morikawa T; Motoi F; Unno M
Pancreatology; 2020 Dec; 20(8):1711-1717. PubMed ID: 33032923
[TBL] [Abstract][Full Text] [Related]
30. Preoperative assessment of para-aortic lymph node metastasis in patients with pancreatic cancer.
Imai H; Doi R; Kanazawa H; Kamo N; Koizumi M; Masui T; Iwanaga Y; Kawaguchi Y; Takada Y; Isoda H; Uemoto S
Int J Clin Oncol; 2010 Jun; 15(3):294-300. PubMed ID: 20232101
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of pancreatic adenocarcinoma that was not resected because of isolated para-aortic lymph node involvement.
Marchese U; Ewald J; Gilabert M; Delpero JR; Turrini O
J Visc Surg; 2019 Apr; 156(2):97-101. PubMed ID: 30026012
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis.
Ye M; Zhang Q; Chen Y; Fu Q; Li X; Bai X; Liang T
HPB (Oxford); 2020 Jun; 22(6):821-832. PubMed ID: 32001139
[TBL] [Abstract][Full Text] [Related]
33. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy.
Hank T; Sandini M; Ferrone CR; Rodrigues C; Weniger M; Qadan M; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
JAMA Surg; 2019 Oct; 154(10):943-951. PubMed ID: 31411659
[TBL] [Abstract][Full Text] [Related]
34. The benefits of neoadjuvant therapy for patients with resectable pancreatic cancer: an updated systematic review and meta-analysis.
Yang B; Chen K; Liu W; Long D; Wang Y; Liu X; Ma Y; Tian X; Yang Y
Clin Exp Med; 2023 Nov; 23(7):3159-3169. PubMed ID: 37310659
[TBL] [Abstract][Full Text] [Related]
35. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
[TBL] [Abstract][Full Text] [Related]
36. Positive para-aortic lymph nodes following pancreatectomy for pancreatic cancer. Systematic review and meta-analysis of impact on short term survival and association with clinicopathologic features.
Agalianos C; Gouvas N; Papaparaskeva K; Dervenis C
HPB (Oxford); 2016 Aug; 18(8):633-41. PubMed ID: 27485057
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery.
Terlizzi M; Buscail E; Boussari O; Adgié S; Leduc N; Terrebonne E; Smith D; Blanc JF; Lapuyade B; Laurent C; Chiche L; Belleannée G; Le Malicot K; Trouette R; Pouypoudat C; Vendrely V
Acta Oncol; 2021 Sep; 60(9):1114-1121. PubMed ID: 34197269
[TBL] [Abstract][Full Text] [Related]
38. [The effect of para-aortic lymph node metastasis on the resectability of pancreatic cancer].
Dai HM; Hong XF; Pang HY; Wu WM; Zhao YP
Zhonghua Wai Ke Za Zhi; 2019 Jan; 57(1):68-71. PubMed ID: 30612394
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant Therapy Versus Upfront Resection for Pancreatic Cancer: The Actual Spectrum and Clinical Burden of Postoperative Complications.
Marchegiani G; Andrianello S; Nessi C; Sandini M; Maggino L; Malleo G; Paiella S; Polati E; Bassi C; Salvia R
Ann Surg Oncol; 2018 Mar; 25(3):626-637. PubMed ID: 29214453
[TBL] [Abstract][Full Text] [Related]
40. Importance of resectability status in neoadjuvant treatment for pancreatic cancer.
Sho M; Akahori T; Tanaka T; Kinoshita S; Nagai M; Tamamoto T; Ohbayashi C; Hasegawa M; Kichikawa K; Nakajima Y
J Hepatobiliary Pancreat Sci; 2015 Jul; 22(7):563-70. PubMed ID: 25921623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
